Alopecia Associated with Fluconazole Therapy

@article{Pappas1995AlopeciaAW,
  title={Alopecia Associated with Fluconazole Therapy},
  author={Peter G. Pappas and Carol A. Kauffman and John R. Perfect and Philip J. Johnson and David S. McKinsey and David M. Bamberger and Richard J. Hamill and Patricia Kay Sharkey and Stanley W. Chapman and J Sobel},
  journal={Annals of Internal Medicine},
  year={1995},
  volume={123},
  pages={354-357}
}
Fluconazole is a triazole compound with broad-spectrum antifungal activity; it was approved by the Food and Drug Administration in 1990 for the treatment of cryptococcal meningitis and mucosal and systemic candidiasis [1]. It has been used extensively in the United States and other countries to treat proven and suspected infection caused by Candida species and Cryptococcus neoformans [2, 3] and as prophylaxis in neutropenic patients [4], recipients of bone marrow and solid organ transplants [5… Expand
Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis
TLDR
The findings from Mycoses Study Group Protocol 20, a comparative trial sponsored by the National Institute of Allergy and Infectious Diseases that compares two antifungal agents, fluconazole and itraconazole, in the treatment of coccidioidomycosis, are presented. Expand
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
TLDR
Importantly 15 years after its introduction in the antifungal armamentarium, fluconazole is still a first line treatment option in several cases of invasive candidiasis and its prophylactic use should however be limited to selected high-risk patients to limit the risk of emergence of azole-resistant strains. Expand
Voriconazole: How to Use This Antifungal Agent and What to Expect.
TLDR
Drawbacks to the use of voriconazole are that it has unpredictable, nonlinear pharmacokinetics with extensive interpatient and intrapatient variation in serum levels, and, as a result, therapeutic drug monitoring is essential when using this agent. Expand
Antifungal agents. Part II. The azoles.
TLDR
Fluconazole and itraconazole have replaced ketoconazole as the therapy of choice for nonmeningeal, non-life-threatening cases of histoplasmosis, blastomycosis, and paracoccidioidomycotic cases and is effective in patients with cryptococcosis and coccidioillosis, including those with meningitis. Expand
Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents
TLDR
Azole antifungals are first-line options in the prophylaxis and treatment of invasive fungal infections and have been associated with peripheral neuropathies, and itraconazole and voriconazole with pancreatitis. Expand
Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.
  • P. Pappas, R. Bradsher, +6 authors W. Dismukes
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1997
TLDR
It is concluded that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis. Expand
Fluconazole Therapy for Histoplasmosis
TLDR
It is concluded that fluconazole therapy for histoplasmosis is only moderately effective and should be reserved for patients who cannot take itraconazole. Expand
Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole.
  • C. Kauffman, P. Pappas, +5 authors W. Dismukes
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1996
TLDR
Fluconazole is only modestly effective for treatment of sporotrichosis and should be considered second-line therapy for the occasional patient who is unable to take itraconazole. Expand
Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections
TLDR
Clinicians treating patients with triazoles should closely follow them, monitor pertinent laboratory tests, and consider measuring drug levels as needed, to ensure that patients are optimally treated with the least amount of toxicity possible. Expand
Endemic mycoses: a treatment update.
TLDR
Itraconazole is the treatment of choice for non-life-threatening Histoplasma capsulatum or Blastomyces dermatitidis infections occurring in immunocompetent individuals and is the most efficient secondary prophylaxis of histoplasmosis in AIDS patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 14 REFERENCES
A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
TLDR
A multicenter randomized trial that compared amphotericin B with fluconazole as treatment for candidemia, with the most common diagnoses being renal failure, nonhematologic cancer, and gastrointestinal disease. Expand
Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.
TLDR
The promising clinical response of patients with various forms of candidiasis or cryptococcosis--together with convenient administration regimens--recommends fluconazole as a useful addition to currently available systemic antifungal therapies, in particular for the treatment of mycoses in patients with AIDS. Expand
Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group.
TLDR
Fluconazole therapy is often effective in suppressing coccidioidal meningitis, and response rates were similar for patients with and without previous therapy, for patients without and without concomitant HIV infection, and for patientswith and without pre-existing hydrocephalus. Expand
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
TLDR
Fluconazole is an effective alternative to amphotericin B as primary treatment of cryptococcal meningitis in patients with AIDS and single-drug therapy with either drug is most effective in patients who are at low risk for treatment failure. Expand
Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.
  • P. Pappas, R. Bradsher, +4 authors W. Dismukes
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1995
TLDR
It is concluded that fluconazole (200 mg to 400 mg daily) given for at least 6 months is moderately effective treatment for blastomycosis. Expand
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.
TLDR
Prophylactic administration of fluconazole to recipients of bone marrow transplants reduces the incidence of both systemic and superficial fungal infections. Expand
Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial
TLDR
There is currently no uniformly accepted or proven approach for prevention of fungal infections in neutropenic patients with acute leukemia and fluconazole is a new triazole antifungal agent with activity against many common fungal pathogens causing infection in patients with severe liver disease. Expand
New Oral Treatments for Dermatophytosis
  • R. Hay
  • Medicine
  • Annals of the New York Academy of Sciences
  • 1988
TLDR
Evaluating the newest orally active antifungals in the light of these comments finds a need for alternative methods of therapy in order to achieve better treatment responses in onychomycosis, in dry-type T. rubrum infections, and in certain other dermatophytoses. Expand
Pharmacology and toxicity of high-dose ketoconazole
TLDR
Neither concentration in serum, toxicity, nor outcome correlated with dose, calculated in milligrams per kilogram at the fixed doses (400-mg increments) under study, suggesting that individual drug disposition was not an important factor in outcome or toxicity. Expand
Itraconazole: pharmacologic studies in animals and humans.
Several pharmacologic studies of itraconazole, an orally active antifungal triazole, were conducted in humans and animals. In dogs and rats, no significant toxic effects were seen at doses of up toExpand
...
1
2
...